Mural Oncology Plc (MURA) Return on Assets ROA from the third quarter of 2025 to third quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Mural Oncology Plc  (NASDAQ: MURA)


Mural Oncology Plc's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Mural Oncology Plc's ROA in the third quarter of 2025?
Mural Oncology Plc recorded a cumulative net loss of $-119 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -106.7%.

However, within the Healthcare sector 771 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4401, from total ROA ranking in the second quarter of 2025 at 4453.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Total Assets Change -66.56 % -61.05 % -49.21 % -43.18 % 1000.54 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -119 -147 -131 -129 -154
Return On Assets (TTM) -106.7 % -101.95 % -73.18 % -61.26 % -63.79 %
MURA's Total Ranking # 4401 # 4453 # 4356 # 4915 # 4372
Total Assets (TTM) in million 66 88 129 165 197
Seq. Total Assets Change -24.9 % -31.88 % -21.93 % -16.28 % -12.51 %
Seq. Net Income Change - - - - -

MURA's 5 Years Annual ROA >> Back to MURA Management Effectiveness >> Compare MURA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 362
Sector # 772
Overall # 4353

Return On Assets Statistics
High Average Low
-59.01 %
-85.77 %
-121.75 %
(Dec 31 2024)   (Mar 31 2024)



  News about Mural Oncology Plc Return on Assets ROA

Mural Oncology: Balancing Innovation and Financial Strain as Clinical Trials Approach,

Mural Oncology: A Gamble in the High-Stakes Game of Immuno-OncologyIn the ever-evolving landscape of cancer treatment, Mural Oncology Plc stands at a precipice of promise and peril. The clinical-stage biotech firm, wading through significant financial turbulence, has staked its future on innovative therapies that could redefine patient outcomes in oncology. As the company progresses with its lead drug candidate, nemvaleukin alfa, to late-stage clinical trials, questions loom large over its financial health and sustainability in an industry that demands not only scientific breakthroughs but fiscal prudence.As of the third quarter of 2024, Mural Oncology has posted a staggering cumulative net loss of $250 million over the past year, leading to an alarming return on assets (ROA) of -103.88%. This scenario starkly contrasts with 749 other healthcare companies that, as of late 2024, report higher ROAs, illuminating the fierce competitive landscape the company must navigate. Despite a slight improvement in its overall ROA ranking—from 4309 in Q2 2024 to 4023 in Q3—it remains a glaring indicator of the challenges facing the firm.



Financial Statements
Mural Oncology Plc's Assets $ 66 million MURA's Balance sheet
Mural Oncology Plc's Income $ -4 million Quarterly MURA's Income Statement
MURA's Income by Division See MURA's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (FY 2012)
FY (Dec. 29, 2012)
FY
FY
Y / Y Total Assets Change -43.18 % - - - -
Total Assets in million 165 290 0 0 0
Y / Y Net Income Change - - - - -
Net Income in million -129 -207 964 0 0
Annual Return On Assets -78.06 % -71.6 % - - -

MURA's 5 Years Annual ROA >> Back to MURA Management Effectiveness >> Compare MURA ROA to its Competitors



More Return On Assets Ratios
MURA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MURA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MURA's Competitors
Subscribers only: Roa for Mural Oncology Plc's Suppliers
Subscribers only: Return On Assets for MURA's Customers

You may also want to know
MURA's Roi MURA's Inventory Turnover Ratio MURA's Growth Rates MURA's Dividend Comparisons
MURA's Profitability Ratios MURA's Asset Turnover Ratio MURA's Dividend Growth
MURA's Roe MURA's Valuation Ratios MURA's Financial Strength Ratios MURA's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector ROA

Date modified: 2026-08-29T17:49:05+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.